H
Hans-Georg Rammensee
Researcher at University of Tübingen
Publications - 144
Citations - 26506
Hans-Georg Rammensee is an academic researcher from University of Tübingen. The author has contributed to research in topics: Antigen & Major histocompatibility complex. The author has an hindex of 66, co-authored 118 publications receiving 25446 citations. Previous affiliations of Hans-Georg Rammensee include Scripps Health & Max Planck Society.
Papers
More filters
Journal ArticleDOI
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.
TL;DR: Each MHC class I allele has its individual rules to which peptides presented in the groove adhere, and this information about the contents of MHC grooves is now provided.
Journal ArticleDOI
SYFPEITHI: database for MHC ligands and peptide motifs.
TL;DR: The first version of the major histocompatibility complex (MHC) databank SYFPEITHI: database for MHC ligands and peptide motifs, is now available to the general public.
Journal ArticleDOI
MHC ligands and peptide motifs: first listing.
TL;DR: A compendium of major histocompatibility complex (MHC) peptide motifs and MHC ligands known to date, together with a discussion of the methods used to gain this information, is provided.
Journal ArticleDOI
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin,Xiuli Zhang,Heiko Schuster,Etienne Caron,Jeffrey P. Ward,Takuro Noguchi,Yulia Ivanova,Jasreet Hundal,Cora D. Arthur,Willem Jan Krebber,Gwenn E. Mulder,Mireille Toebes,Matthew D. Vesely,Samuel S. K. Lam,Alan J. Korman,James P. Allison,Gordon J. Freeman,Arlene H. Sharpe,Erika L. Pearce,Ton N. Schumacher,Ruedi Aebersold,Hans-Georg Rammensee,Cornelis J. M. Melief,Elaine R. Mardis,William E. Gillanders,Maxim N. Artyomov,Robert D. Schreiber +26 more
TL;DR: Tumour-specific mutant proteins are identified as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and it is shown that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy.
Journal ArticleDOI
Peptides Naturally Presented by MHC Class I Molecules
TL;DR: The peptide specificity of class I molecules and experimental evidence indicate that T cells are tolerant to only a small fraction of the expressed genomic sequences and are not tolerant to the remainder.